{"nct_id":"NCT01985126","title":"An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD","status":"COMPLETED","status_verified_date":"2018-06","start_date":"2013-09-27","start_date_type":"ACTUAL","primary_completion_date":"2015-01-09","primary_completion_date_type":"ACTUAL","completion_date":"2017-05-30","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["JNJ"]}